Notice of Investor Webinar

16 September 2026

Kromek Group plc 

(“Kromek” or the “Company” or the “Group”) 

Notice of Investor Webinar

Kromek Group plc (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces that Arnab Basu, CEO, and Claire Burgess, CFO, will be hosting an online Q&A session for investors at 4.00pm BST on Monday 21 September 2026 via the Kromek Investor Hub. This follows the release of the Group’s final results for the year ended 30 April 2026 on 14 September 2026.

A pre-recorded results presentation will be uploaded to the Kromek Investor Hub on Friday 18 September 2026 and will be accessible here: https://investors.kromek.com/webinars/epJYXP-kromek-final-results-2026-presentation.

Shareholders can register to attend the live Q&A session, or pre-submit questions, via the registration page here: https://investors.kromek.com/webinars/PwblAr-kromek-final-results-2026-live-q-a.

Questions can also be asked live during the Q&A session.

For further information, please contact: 

Engage with the Kromek management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our interactive investor
hub here: https://investors.kromek.com/

Subscribe to our news alert service: https://investors.kromek.com/auth/signup

Kromek Group plc 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.